Perkins Capital Management Inc. Sells 750 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Perkins Capital Management Inc. decreased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 8.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,441 shares of the specialty pharmaceutical company’s stock after selling 750 shares during the period. Perkins Capital Management Inc.’s holdings in ANI Pharmaceuticals were worth $467,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Victory Capital Management Inc. raised its stake in ANI Pharmaceuticals by 153.6% in the third quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock worth $771,000 after buying an additional 7,825 shares in the last quarter. Natixis Advisors LLC raised its position in shares of ANI Pharmaceuticals by 56.2% in the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock worth $1,085,000 after acquiring an additional 6,545 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in ANI Pharmaceuticals by 99.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 13,470 shares of the specialty pharmaceutical company’s stock valued at $804,000 after purchasing an additional 6,728 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in ANI Pharmaceuticals in the third quarter valued at about $751,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ANIP. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target for the company. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 price target on the stock. Guggenheim raised their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price on the stock. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $64.26 on Monday. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -116.84 and a beta of 0.63. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock’s fifty day moving average price is $59.39 and its 200 day moving average price is $58.10. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,200 shares of company stock worth $191,776. 12.70% of the stock is currently owned by insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.